• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Oyster Point takes aim at the root of dry eye disease with intranasal drug-delivery technique

July 12, 2018 By Sarah Faulkner

Oyster Point Pharma logoLarge pharmaceutical companies dominate the dry eye disease space – Allergan (NYSE:AGN) rakes in more than a billion dollars every year for its Restasis eye drops.

Eight-person Oyster Point Pharma wants in on that market. But it’s betting on a completely different approach.

“What we’ve come up with is a very innovative nasal spray, which when sprayed into the nose penetrates the naval cavity quite rapidly, binds to the [nicotinic acetylcholine] receptors, and can actually stimulate the patient’s natural tear production,” CEO Jeffrey Nau told Drug Delivery Business News. “It’s really the first of its kind in the pharmaceutical field to use this class of drugs to stimulate those receptors on the trigeminal nerve.”

Early data have been promising, the chief executive said. Oyster Point today touted data from a dose-ranging Phase IIb study showing that its nasal spray demonstrated a statistically significant reduction in the signs and symptoms of dry eye disease compared to a control spray.

The nasal spray sends Oyster Point’s nicotinic acetylcholine receptor agonist directly to the point where the nasal cavity connects to the eye – along the trigeminal parasympathetic pathway. There, the drug binds to nicotinic acetylcholine receptors and triggers natural tear production, Nau explained.

Eye drops, like Allergan’s Restasis product, are the standard of care for dry eye disease. But Nau noted that topical drug delivery to the eye isn’t always ideal for patients.

Oyster Point CEO Jeffrey Nau
Nau

“If you’re a dry eye patient or you’re a patient that just underwent surgery or you’re a patient that wears contact lenses, delivering drugs by a drop or two to the front of the eye has a number of different challenges,” he said. “So delivering through any other novel mechanism is really exciting because we can spare the ocular surface. We don’t have to worry about whether the drug is sticking to the contact lenses. We don’t have to worry about whether this drug stings the surface of the eye. If you’re a dry eye patient who already has some discomfort, the last thing you want to do is put a drop on your eye that stings.”

Nasal sprays, like eye drops, are usable and familiar to most people, he added.

“Most patients through the course of their life, whether in childhood or early adulthood, have experience with a nasal spray somewhere along the way, whether it be for sinus congestion or allergies. So for most of us, nasal sprays are not foreign. I think that technology now with delivering nasal sprays provides a very comfortable mist in the nose, and one of the nice things about our product is you don’t have to get lots of drugs deep into the nose because we’re not treating a disease which is located back in the sinus cavity,” Nau said.

In the company’s latest, 165-person study, researchers saw a positive correlation between the dose of drugs and tear film production. They also correlated treatment with Oyster Point’s nasal spray with a reduction in symptoms.

“As far as we know, this is the first drug that’s ever been able to show not only an increase in tear production but a decrease in a patient’s symptoms that’s directly correlated to the dose of drug that they were given,” Nau said.

To stand up against a powerhouse company like Allergan, Nau explained that Oyster Point has taken a more direct attempt at treating dry eye disease.

“Most of the other therapies that are out there are not necessarily addressing the fundamental root cause of dry eye disease, which is the instability or the breakdown for that tear film tri-layer. They’re going after really what I would characterize as the sequelae of the disease, which is once that tear film layer breaks down, you get inflammation, you get irritation – that’s really downstream,” Nau said.

“What sets us apart is we’re actually stimulating the patient to produce their own natural tear film. What we hope to do is not only bring those patients that have dry eye disease back to a healthy state, but we hope to also stop those patients from moving down this disease continuum and getting into that chronic dry eye disease state because we’re able to put tear film that’s healthy and stable on their eye a number of times a day,” he added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: Allergan, oysterpointpharma

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Reader Interactions

Comments

  1. Addison says

    January 18, 2019 at 3:57 am

    please let me know the best way to cure dry eye disease problem via medicine.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS